(MENAFN- GlobeNewsWire - Nasdaq) Growth opportunities center on expanded genetic panels, telehealth-enabled regional access, lab automation, awareness campaigns and integration with hospital prenatal care.Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Australia Non-Invasive Prenatal Testing Market Report by Component, Application, End User, States and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering.
The Australia Non-Invasive Prenatal Testing (NIPT) Market is projected to grow from US$80.80 million in 2025 to US$247.21 million by 2034, registering a Compound Annual Growth Rate (CAGR) of 13.23% from 2026 to 2034. Market expansion is being supported by rising awareness of prenatal genetic screening, increasing maternal age, advances in genomic sequencing, and broader access to prenatal healthcare services.
NIPT is increasingly integrated into prenatal care to screen for chromosomal conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), Patau syndrome (Trisomy 13), and selected sex chromosome abnormalities. Its high screening accuracy, early testing capabilities, and favorable safety profile have strengthened adoption among expectant parents, obstetricians, maternal-fetal medicine specialists, and genetic counselors.
Australia NIPT Industry Outlook
Australia's established healthcare infrastructure, expanding diagnostic laboratory network, and strong focus on preventive and personalized medicine provide a supportive environment for NIPT market growth. Hospitals, fertility clinics, diagnostic laboratories, and specialist prenatal care providers are increasing access to advanced chromosomal and genetic screening services.
Technological progress in next-generation sequencing, molecular diagnostics, laboratory automation, and bioinformatics is improving test reliability, processing capacity, and turnaround times. These advances are also supporting broader screening panels that extend beyond common trisomies to selected inherited conditions and genome-wide abnormalities.
The acquisition of Yourgene Health plc by Novacyt in 2023 also strengthened the enlarged group's prenatal testing portfolio. The combined organization has complementary capabilities across NIPT, Ranger Technology, and PCR solutions, positioning it to support further development and commercialization of prenatal screening products.
Recent Product and Service Developments
28-May-25 - Australian Red Cross Lifeblood: Launched a national RhD Non-Invasive Prenatal Testing (RhD NIPT) service for RhD-negative pregnant women, enabling fetal RhD status assessment through maternal blood testing. Aug-25 - Natera: Introduced the Fetal Focus 5-Gene sgNIPT panel for five inherited genetic disorders, with availability extending to international clinical users, including those in Australia. 31-Oct-25 - Natera: Expanded the Fetal Focus offering from 5 to 20 genes, broadening screening coverage for inherited diseases. Nov-25 - Australian Red Cross Lifeblood: Introduced a Massively Parallel Sequencing (MPS) antigen panel for clinically significant fetal blood group antigens. IVF Australia: Expanded access to Panorama NIPT for trisomies, Turner syndrome, and triploidy. Victorian Clinical Genetics Services (VCGS): Enhanced the Percept NIPT program to support broader chromosomal abnormality assessment. Sonic Genetics: Broadened deployment of genome-wide prenatal screening services in Australia. Australian Clinical Labs: Introduced advanced NIPT screening panels covering additional chromosomal and genetic conditions. Monash IVF Group and Virtus Health / IVF Australia: Expanded prenatal genetic screening capabilities across fertility and prenatal care programs.
Key Australia Non-Invasive Prenatal Testing Market Drivers
Growing public awareness: Healthcare education, maternal health initiatives, digital outreach, and genetic counseling are improving awareness of prenatal screening options. Better access to reliable clinical information is helping expectant parents make informed decisions and increasing demand for NIPT across Australia.
Improved regional healthcare access: Telehealth, regional diagnostic networks, remote consultations, and more efficient laboratory logistics are extending prenatal genetic screening into rural and regional communities. These services reduce travel requirements and improve access to specialist advice, sample collection, and test results.
Advances in genomic screening: Continued investment in sequencing platforms, automated sample preparation, molecular testing, and bioinformatics is increasing laboratory efficiency and screening performance. Innovation is also enabling providers to assess a wider range of chromosomal and inherited conditions.
Rising maternal age: Australia's changing maternal demographics are contributing to increased demand for early chromosomal screening. NIPT is frequently incorporated into prenatal care pathways for patients seeking additional information about fetal chromosomal health.
Market Challenges
Testing costs: Out-of-pocket expenses remain a barrier for some families, particularly where private insurance or reimbursement is limited. Wider coverage, improved reimbursement pathways, and lower processing costs could support more equitable access to NIPT services.
Regional awareness gaps: Some remote communities continue to face limited access to prenatal education, specialist consultations, and genetic counseling. Expanded telehealth programs, community outreach, and regional clinical partnerships will be important for reducing disparities in NIPT utilization.
Market Segment Outlook
The instruments segment is benefiting from investment in next-generation sequencing systems, polymerase chain reaction platforms, automated sample preparation equipment, and bioinformatics solutions. Hospitals and diagnostic laboratories are upgrading genomic testing infrastructure to meet rising screening volumes and improve operational efficiency.
The services segment is expected to expand as NIPT becomes more established within maternal healthcare. Specialized laboratories, genetic counseling providers, fertility clinics, and hospitals are strengthening service delivery through improved methodologies and faster result reporting.
Down syndrome screening remains a major application because Trisomy 21 is among the most frequently assessed chromosomal conditions. Hospitals are expected to retain a prominent end-user position due to their role in prenatal consultation, sample collection, maternal-fetal medicine, counseling, and follow-up care.
Regional Market Highlights
New South Wales: A large population, extensive maternity care network, advanced laboratories, and access to genomic research support a leading market position. Victoria: Strong medical research capabilities, specialist genetic services, and investment in prenatal diagnostics are accelerating NIPT adoption. Queensland: Telehealth programs and regional healthcare expansion are improving access across urban, regional, and remote communities. Western Australia: Partnerships between metropolitan hospitals, regional facilities, and specialist laboratories are supporting wider service availability. Other markets: South Australia, the Australian Capital Territory, Tasmania, and the Northern Territory offer additional growth opportunities as prenatal screening access expands.
Australia NIPT Market Segmentation
By Component
Instruments Kits and Reagents Services
By Application
Down Syndrome (Trisomy 21) Edwards Syndrome (Trisomy 18) Patau Syndrome (Trisomy 13) Turner Syndrome Other Applications
By End User
Hospitals Diagnostic Labs
Key Players in the Australia Non-Invasive Prenatal Testing Market
Eurofins Scientific F. Hoffmann-La Roche Ltd Invitae Corporation Illumina Inc. Natera Inc. Centogene NV Qiagen
Competitive analysis covers company overviews, key personnel, recent developments, SWOT analysis, and revenue analysis. As clinical adoption broadens and genomic technologies continue to advance, Australia's NIPT market is positioned for sustained growth through 2034.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment